Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies
- PMID: 11085200
- DOI: 10.2165/00003495-200060040-00005
Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies
Abstract
Oxaliplatin is a platinum compound that inhibits DNA synthesis, primarily by causing intrastrand cross-links in DNA. Oxaliplatin has a broad spectrum of antineoplastic activity and has demonstrated a lack of cross-resistance with other platinum compounds. In patients with metastatic colorectal cancer, intravenous oxaliplatin has been trialled as a monotherapy and in combination with other agents. The highest response rates were achieved when oxaliplatin was used in combination with fluorouracil/folinic acid (leucovorin; calcium folinate), typically > or = 50% in the first-line setting and 13 to 45% as a second-line therapy. First-line triple therapy with oxaliplatin and fuorouracil/folinic acid achieved significantly higher response rates and longer median progression-free survival than fluorouracil/folinic acid therapy alone. However, no significant difference in the median duration of overall survival was found. This may be a consequence of the subsequent use of oxaliplatin and/or surgery after disease progression in patients who relapsed after fluorouracil/folinic acid therapy alone. Neoadjuvant therapy with oxaliplatin/fluorouracil/folinic acid has proven beneficial in enabling surgical removal of previously unresectable liver metastases. In 2 studies, surgery with curative intent was performed in 16 and 51% of patients with initially unresectable liver metastases following oxaliplatin/fluorouracil/folinic acid therapy; the 5-year survival rates were 40 and 50%, respectively. In patients with advanced ovarian cancer, first-line therapy with oxaliplatin/cyclophosphamide achieved an objective response rate which did not differ significantly from that of cisplatin/cyclophosphamide (33 vs 42%). In addition, oxaliplatin has shown efficacy in patients with platinum-pretreated ovarian cancer and achieved objective response rates similar to paclitaxel in this setting (16 vs 17%). Promising results have also been found with oxaliplatin in patients with non-Hodgkin's lymphoma, breast cancer, mesothelioma and non-small cell lung cancer. Reversible, cumulative, peripheral sensory neuropathy is the principle dose-limiting factor of oxaliplatin therapy. Haematological and gastrointestinal toxicities occur frequently but are generally mild to moderate in intensity.
Conclusion: Oxaliplatin in combination with fluorouracil/folinic acid is an effective treatment option for patients with metastatic colorectal cancer, both as a first-line therapy and in patients refractory to previous chemotherapy. Although preliminary results failed to show any overall survival advantage of this regimen over fluorouracil/folinic acid alone, this may be a consequence of trial design and requires further examination. Additional clinical investigation of oxaliplatin in patients with other cancers is warranted given the promising results achieved in early trials, most notably in patients with platinum-pretreated ovarian cancer.
Similar articles
-
Oxaliplatin: a review of its use in the management of metastatic colorectal cancer.Drugs Aging. 1999 Jun;14(6):459-75. doi: 10.2165/00002512-199914060-00006. Drugs Aging. 1999. PMID: 10408744 Review.
-
Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer.Drugs. 2003;63(19):2127-56. doi: 10.2165/00003495-200363190-00013. Drugs. 2003. PMID: 12962525 Review.
-
Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.Prescrire Int. 2005 Dec;14(80):230-3. Prescrire Int. 2005. PMID: 16400749
-
Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial.Med Sci Monit. 2010 Feb;16(2):CR49-55. Med Sci Monit. 2010. PMID: 20110914 Clinical Trial.
-
Oxaliplatin: a review of preclinical and clinical studies.Ann Oncol. 1998 Oct;9(10):1053-71. doi: 10.1023/a:1008213732429. Ann Oncol. 1998. PMID: 9834817 Review.
Cited by
-
What is the Reason That the Pharmacological Future of Chemotherapeutics in the Treatment of Lung Cancer Could Be Most Closely Related to Nanostructures? Platinum Drugs in Therapy of Non-Small and Small Cell Lung Cancer and Their Unexpected, Possible Interactions. The Review.Int J Nanomedicine. 2024 Sep 14;19:9503-9547. doi: 10.2147/IJN.S469217. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39296940 Free PMC article. Review.
-
Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold.Mol Cancer. 2024 Jan 10;23(1):10. doi: 10.1186/s12943-023-01919-3. Mol Cancer. 2024. PMID: 38200602 Free PMC article.
-
Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat.J Pain. 2009 May;10(5):534-41. doi: 10.1016/j.jpain.2008.12.003. Epub 2009 Feb 23. J Pain. 2009. PMID: 19231296 Free PMC article.
-
Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer.Med Oncol. 2012 Dec;29(4):2831-7. doi: 10.1007/s12032-012-0197-9. Epub 2012 Mar 4. Med Oncol. 2012. PMID: 22392197 Clinical Trial.
-
Design, Synthesis, and Anticancer Effect Studies of Iridium(III) Polypyridyl Complexes against SGC-7901 Cells.Molecules. 2019 Aug 28;24(17):3129. doi: 10.3390/molecules24173129. Molecules. 2019. PMID: 31466318 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical